Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.82 |
| ▸ | MEN1 | O00255 | 5/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.82 |
| ▸ | MAPT | P10636 | 5/20 | 0.82 |
| ▸ | HPGD | P15428 | 5/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.82 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.82 |
| ▸ | RECQL | P46063 | 5/20 | 0.82 |
| ▸ | BLM | P54132 | 5/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.82 |
| ▸ | TP53 | P04637 | 4/20 | 0.82 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.82 |
| ▸ | PMP22 | Q01453 | 4/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6599711 | 1.00 | EGFR (0.82) | EGFRKDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL30274781 | 1.00 | EGFR (0.82) | EGFRKDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL645291 | 0.90 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL29378814 | 0.90 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL645290 | 0.90 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL21277338 | 0.89 | EGFR (0.84) | EGFRKDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL2533402 | 0.87 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL6055311 | 0.87 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL29376415 | 0.87 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL3486952 | 0.87 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2026-05-28 | — | — | US | claimed |
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2026-01-08 | — | — | US | claimed |
| US-20250381283-A1 | METHOD FOR TREATING SOLID TUMOR | BIO THERA SOLUTIONS LTD (CN) | 2025-12-18 | — | — | US | claimed |
| US-20250333498-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2025-10-30 | — | — | US | claimed |
| US-20250262316-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2025-08-21 | — | — | US | claimed |
| US-20250249114-A1 | METHOD FOR TREATING HER2-POSITIVE SOLID TUMOR | BIO-THERA SOLUTIONS, LTD. (CN) | 2025-08-07 | — | — | US | claimed |
| EP-4556027-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | Bio-Thera Solutions, Ltd. (CN) | 2025-05-21 | — | — | EP | claimed |
| EP-4545099-A1 | METHOD FOR TREATING SOLID TUMOR | Bio-Thera Solutions, Ltd. (CN) | 2025-04-30 | — | — | EP | claimed |
| EP-4538291-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Bio-Thera Solutions, Ltd. (CN) | 2025-04-16 | — | — | EP | claimed |
| EP-4534105-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Bio-Thera Solutions, Ltd. (CN) | 2025-04-09 | — | — | EP | claimed |
| US-20250059274-A1 | ANTI-FRa ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2025-02-20 | — | — | US | claimed |
| EP-4509141-A1 | METHOD FOR TREATING HER2-POSITIVE SOLID TUMOR | Bio-Thera Solutions, Ltd. (CN) | 2025-02-19 | — | — | EP | claimed |
| EP-4455164-A1 | ANTI-FRalpha ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Bio-Thera Solutions, Ltd. (CN) | 2024-10-30 | — | — | EP | claimed |
| US-20240269315-A1 | DRUG CONJUGATE AND USE THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2024-08-15 | — | — | US | claimed |
| EP-4349371-A1 | DRUG CONJUGATE AND USE THEREOF | Bio-Thera Solutions, Ltd. (CN) | 2024-04-10 | — | — | EP | claimed |
| WO-2023232080-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 百奥泰生物制药股份有限公司 | 2023-12-07 | — | — | WO | claimed |
| WO-2023116911-A1 | ANTI-FRα ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 百奥泰生物制药股份有限公司 | 2023-06-29 | — | — | WO | claimed |
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | claimed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | NECTIN4, VSIG8, IGSF11 | EGFR 1917/4885KDM4E 1440/4885MEN1 1693/4885 |
| US-20250249114-A1 | METHOD FOR TREATING HER2-POSITIVE SOLID TUMOR | ERBB2, EGFR, ERBB3 | EGFR 2/4885KDM4E 3617/4885MEN1 2613/4885 |
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | NECTIN4, CD22, NGFR | EGFR 467/4885KDM4E 4366/4885MEN1 1105/4885 |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | EGFR 2486/4885KDM4E 2489/4885MEN1 3673/4885 |
| US-20250333498-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | CNTN1, EPCAM, SLC22A8 | EGFR 1984/4885KDM4E 2741/4885MEN1 2360/4885 |
| US-20240269315-A1 | DRUG CONJUGATE AND USE THEREOF | CD47, SLC10A1, SSB | EGFR 147/4885KDM4E 1362/4885MEN1 326/4885 |
| US-20250381283-A1 | METHOD FOR TREATING SOLID TUMOR | TPM4, TPM3, TPST2 | EGFR 250/4885KDM4E 4103/4885MEN1 2103/4885 |
| US-20250059274-A1 | ANTI-FRa ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | FOLR1, FOLR2, DHFR | EGFR 117/4885KDM4E 4761/4885MEN1 4451/4885 |
| US-20250262316-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | FCGR2A, FCGR1A, FCGR3B | EGFR 49/4885KDM4E 2333/4885MEN1 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.